NASDAQ:CLPT ClearPoint Neuro (CLPT) Stock Price, News & Analysis $10.00 -0.40 (-3.85%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.07 +0.07 (+0.75%) As of 08/1/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ClearPoint Neuro Stock (NASDAQ:CLPT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ClearPoint Neuro alerts:Sign Up Key Stats Today's Range$9.94▼$10.3350-Day Range$10.00▼$13.9352-Week Range$6.25▼$19.22Volume270,115 shsAverage Volume350,363 shsMarket Capitalization$279.90 millionP/E RatioN/ADividend YieldN/APrice Target$19.67Consensus RatingBuy Company Overview ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California. Read More ClearPoint Neuro Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreCLPT MarketRank™: ClearPoint Neuro scored higher than 54% of companies evaluated by MarketBeat, and ranked 448th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingClearPoint Neuro has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageClearPoint Neuro has only been the subject of 1 research reports in the past 90 days.Read more about ClearPoint Neuro's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ClearPoint Neuro are expected to grow in the coming year, from ($0.66) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ClearPoint Neuro is -13.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ClearPoint Neuro is -13.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClearPoint Neuro has a P/B Ratio of 10.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ClearPoint Neuro's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.40% of the outstanding shares of ClearPoint Neuro have been sold short.Short Interest Ratio / Days to CoverClearPoint Neuro has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in ClearPoint Neuro has recently decreased by 5.48%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldClearPoint Neuro does not currently pay a dividend.Dividend GrowthClearPoint Neuro does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.40% of the outstanding shares of ClearPoint Neuro have been sold short.Short Interest Ratio / Days to CoverClearPoint Neuro has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in ClearPoint Neuro has recently decreased by 5.48%, indicating that investor sentiment is improving significantly. News and Social Media3.5 / 5News Sentiment1.22 News SentimentClearPoint Neuro has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ClearPoint Neuro this week, compared to 2 articles on an average week.Search Interest5 people have searched for CLPT on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows1 people have added ClearPoint Neuro to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ClearPoint Neuro insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $415,173.00 in company stock.Percentage Held by InsidersOnly 6.97% of the stock of ClearPoint Neuro is held by insiders.Percentage Held by InstitutionsOnly 30.08% of the stock of ClearPoint Neuro is held by institutions.Read more about ClearPoint Neuro's insider trading history. Receive CLPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ClearPoint Neuro and its competitors with MarketBeat's FREE daily newsletter. Email Address CLPT Stock News HeadlinesMove Over, Magnificent 7: The Frontier 7 Will Redefine Our FutureJuly 10, 2025 | 247wallst.comClearPoint Neuro, Inc. (CLPT) - Yahoo FinanceJuly 8, 2025 | finance.yahoo.comThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains. | Weiss Ratings (Ad)ClearPoint Neuro: Consumables Growth Is PromisingJune 27, 2025 | seekingalpha.comClearPoint Neuro, Inc. (CLPT): A Bull Case TheoryJune 11, 2025 | finance.yahoo.comLake Street says AMT-130 could be ‘significantly impactful’ for ClearPointJune 4, 2025 | finance.yahoo.comClearPoint Neuro Updates Director Compensation PlanMay 19, 2025 | tipranks.comClearPoint Neuro First Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsMay 17, 2025 | uk.finance.yahoo.comSee More Headlines CLPT Stock Analysis - Frequently Asked Questions How have CLPT shares performed this year? ClearPoint Neuro's stock was trading at $15.38 on January 1st, 2025. Since then, CLPT stock has decreased by 35.0% and is now trading at $10.00. How were ClearPoint Neuro's earnings last quarter? ClearPoint Neuro, Inc. (NASDAQ:CLPT) released its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.07. The company earned $8.49 million during the quarter, compared to the consensus estimate of $8.21 million. ClearPoint Neuro had a negative trailing twelve-month return on equity of 78.09% and a negative net margin of 64.51%. Read the conference call transcript. Who are ClearPoint Neuro's major shareholders? ClearPoint Neuro's top institutional investors include Lane Generational LLC (0.92%), Taylor Frigon Capital Management LLC (0.64%), Conway Capital Management Inc. (0.59%) and Parsons Capital Management Inc. RI (0.51%). Insiders that own company stock include Joseph Michael Burnett, Joseph Burnett and Timothy T Richards. View institutional ownership trends. How do I buy shares of ClearPoint Neuro? Shares of CLPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ClearPoint Neuro own? Based on aggregate information from My MarketBeat watchlists, some other companies that ClearPoint Neuro investors own include Arista Networks (ANET), NVIDIA (NVDA), CrowdStrike (CRWD), Axon Enterprise (AXON), Advanced Micro Devices (AMD), Cadence Design Systems (CDNS) and Broadcom (AVGO). Company Calendar Last Earnings5/13/2025Today8/01/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:CLPT CIK1285550 Webwww.clearpointneuro.com Phone(949) 900-6833Fax949-900-6834Employees110Year FoundedN/APrice Target and Rating Average Price Target for ClearPoint Neuro$19.67 High Price Target$30.00 Low Price Target$9.00 Potential Upside/Downside+96.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.91 million Net Margins-64.51% Pretax Margin-64.50% Return on Equity-78.09% Return on Assets-51.33% Debt Debt-to-Equity RatioN/A Current Ratio3.53 Quick Ratio2.57 Sales & Book Value Annual Sales$31.39 million Price / Sales8.92 Cash FlowN/A Price / Cash FlowN/A Book Value$0.92 per share Price / Book10.87Miscellaneous Outstanding Shares27,990,000Free Float26,038,000Market Cap$279.90 million OptionableOptionable Beta0.85 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:CLPT) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ClearPoint Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ClearPoint Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.